What's new
Learn how to decide between nickel- and cobalt-based IMAC resins for your his-tagged purification.
06/17/2019
Learn about the first large-scale antibiotic resistance survey of European urban wastewater treatment plants using highly parallel qPCR.
06/03/2019
Summary of two recent papers describing the use of plasma-seq technology for cancer research.
05/21/2019
Researchers at the University of Helsinki, Universidade Católica Portuguesa, CBQF, and Technische Universität Dresden, Institute of Hydrobiology, along with other collaborators have performed the first trans-Europe surveillance study on antibiotic resistance utilizing the SmartChip Real-Time PCR System.
05/16/2019
Research spotlight
The immune system doesn't innately recognize that cancer cells are abnormal, but now researchers can genetically modify a person's own immune cells to attack cancer cells. This type of immunotherapy is recognized as a promising strategy for the treatment of a variety of cancers...and that's Good Science!
Good science begins with selecting the right methods and reagents, especially when research targets are challenging. In this work, cancer researchers developed a method to amplify challenging BRCA targets, including those that are GC-rich or over 13 kb in length, using two-step PCR under a single set of conditions.
From sample prep and biomarker discovery to single-cell analysis, genetic and epigenetic analysis, HLA typing, T-cell therapy and profiling, gene editing, and antibody therapeutics: browse techniques and reagents for cancer research.
Cancer immunotherapy is a promising approach for cancer treatment and holds several key advantages over traditional therapies, including high specificity, little or no side effects, and a good safety profile.
Takara Bio Inc. (TBI), the parent company in the Takara Bio Group of companies, is leading the way in the fight against cancer by developing technologies and conducting clinical trials.
©2019 Takara Bio Inc. All Rights Reserved.
Region - North America Privacy Policy Terms and Conditions Terms of Use
Creating cancer killers
The immune system doesn't innately recognize that cancer cells are abnormal, but now researchers can genetically modify a person's own immune cells to attack cancer cells. This type of immunotherapy is recognized as a promising strategy for the treatment of a variety of cancers...and that's Good Science!
Optimizing materials and methods for cancer research
Good science begins with selecting the right methods and reagents, especially when research targets are challenging. In this work, cancer researchers developed a method to amplify challenging BRCA targets, including those that are GC-rich or over 13 kb in length, using two-step PCR under a single set of conditions.
Read about how the researchers developed their long-range PCR protocol for BRCA1 and BRCA2
